ANDA Guidance: Reference Listed Drug Vs. Reference Standard Explained
Executive Summary
US FDA’s Orange Book will clarify which drugs are reference listed drugs for use in demonstrating sameness, and which are reference standards for purposes of in vivo bioequivalence testing.
You may also be interested in...
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.